Research programme: AMPA receptor agonists - RespireRx

Drug Profile

Research programme: AMPA receptor agonists - RespireRx

Alternative Names: Ampakines; CX 929; CX1501; CX1763; CX1796; CX1837; CX1846; CX1942; CX2007; CX2076; CX516; CX614; CX707

Latest Information Update: 06 Apr 2016

Price : $50

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; RespireRx Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action AMPA receptor agonists; Brain derived neurotrophic factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory insufficiency; Spinal cord injuries
  • No development reported Alzheimer's disease; Anxiety disorders; Attention-deficit hyperactivity disorder; Fragile X syndrome; Huntington's disease; Major depressive disorder; Mild cognitive impairment; Parkinson's disease; Rett syndrome; Schizophrenia; Sleep apnoea syndrome; Stroke
  • Discontinued Autistic disorder; Chronic brain damage

Most Recent Events

  • 01 Apr 2016 Preclinical development is ongoing for Spinal cord injuries in USA
  • 17 Dec 2015 Cortex Pharmaceuticals is now called RespireRx Pharmaceuticals
  • 30 Jun 2015 Cortex Pharmaceuticals receives research grant from the Canadian Institutes of Health Research for CX 1942 and other related compounds in Respiratory insufficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top